Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Fragmin

Known as: Fragmine 
 
National Institutes of Health

Related topics

Related topics

6 relations
0.6 ML Dalteparin Sodium 25000 UNT/ML Prefilled Syringe [Fragmin]1 ML Dalteparin Sodium 10000 UNT/ML Prefilled Syringe [Fragmin]

Broader (4)

Actin-Binding ProteinDalteparinDalteparin SodiumHeparin, Low-Molecular-Weight

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
Venous thromboembolism in the ICU: main characteristics, diagnosis and thromboprophylaxis
Venous thromboembolism (VTE), including pulmonary embolism (PE) and deep venous thrombosis (DVT), is a common and severe… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Highly Cited
2004
Highly Cited
2004
Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS).
PURPOSE In experimental systems, interference with coagulation can affect tumor biology. Furthermore, it has been suggested that… Expand
Highly Cited
1997
Highly Cited
1997
Thromboprophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies.
Venous thromboembolic disease remains the commonest cause of maternal death. The management of thromboprophylaxis in high risk… Expand
Highly Cited
1997
Highly Cited
1997
Low-Molecular-Weight Heparin (Fragmin) During Instability in Coronary Artery Disease (FRISC)
This study evaluated whether the low-molecular-weight (LMW) heparin dalteparin sodium (Fragmin) had protective effects against… Expand
Highly Cited
1994
Highly Cited
1994
Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis.
Two hundred and four consecutive patients with venographically confirmed deep vein thrombosis (DVT) were randomised either to a… Expand
Highly Cited
1990
Highly Cited
1990
Two daily subcutaneous injections of fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis (DVT).
In a prospective, randomized, open study 119 consecutive patients with phlebographically verified deep venous thrombosis (DVT) of… Expand
Highly Cited
1989
Highly Cited
1989
Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin). Results of a double-blind randomized study.
We performed a prospective, randomized, double-blind trial in 194 unselected patients to determine the safety and efficacy of low… Expand
  • table 1
  • figure 2
  • table 2
  • figure 1
  • table 3
Highly Cited
1987
Highly Cited
1987
Pharmacokinetics of heparin and low molecular weight heparin fragment (Fragmin) in rabbits with impaired renal or metabolic clearance.
The kinetics and tissue distribution of 3H-heparin and a 3H-labelled low molecular weight heparin fragment were compared in… Expand
Highly Cited
1986
Highly Cited
1986
Low molecular weight heparin (KABI 2165, Fragmin): pharmacokinetics after intravenous and subcutaneous administration in human volunteers.
The pharmacokinetics of a low molecular weight heparin (LMWH) with a mean mw of 4000-6000 D (KABI 2165, Fragmin) was studied in 6… Expand
Highly Cited
1980
Highly Cited
1980
Fragmin: a calcium ion sensitive regulatory factor on the formation of actin filaments.
Physarum actinin previously isolated [Hatano, S., & Owaribe, K. (1976) in Cell Motility (Goldman, R., Pollard, T., & Rosenbaum, J… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE